REFERENCES
- Levine J. S., Branch D. W., Rauch J. The antiphospholipid syndrome. N Engl J Med 2002; 346: 752–63
- Mackworth‐Young C. G. Antiphospholipid syndrome: multiple mechanisms. Clin Exp Immunol 2004; 136: 393–401
- Alarcon‐Segovia D., Cabral A. R. The concept and classification of antiphospholipid/cofactor syndromes. Lupus 1996; 5: 364–7
- Marai I., Zandman‐Goddard G., Shoenfeld Y. The systemic nature of the antiphospholipid syndrome. Scand J Rheumatol 2004; 33: 365–72
- Tan E. M., Cohen A. S., Fries J. F., Masi A. T., McShane D. J., Rothfield N. F., et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271–7
- Perdriger A., Werner‐Leyval S., Rollot‐Elamrani K. The genetic basis for systemic lupus erythematosus. Joint Bone Spine 2003; 70: 103–8
- Salazar‐Paramo M., Garcia de la Torre I., Fritzler M. J., Loyau S., Angles‐Cano E. Antibodies to fibrin‐bound tissue‐type plasminogen activator in systemic lupus erythematosus are associated with Raynaud's phenomenon and thrombosis. Lupus 1996; 5: 275–8
- Priori R., Medda E., Conti F., Cassara E. A., Danieli M. G., Gerli R., et al. Familial autoimmunity as a risk factor for systemic lupus erythematosus and vice versa: a case–control study. Lupus 2003; 12: 735–40
- Kohler HP G. P. Plasminogen‐activator inhibitor type 1 and coronary artery disease. N Engl J Med 2000; 342: 1792–801
- Foy C. A., Grant P. J. PCR‐RFLP detection of PAI‐2 gene variants: prevalence in ethnic groups and disease relationship in patients undergoing coronary angiography. Thromb Haemost 1997; 77: 955–8
- Yu H., Maurer F., Medcalf R. L. Plasminogen activator inhibitor type 2: a regulator of monocyte proliferation and differentiation. Blood 2002; 99: 2810–18
- Buyru N., Altinisik J., Gurel C. B., Ulutin T. PCR‐RFLP detection of PAI‐2 variants in myocardial infarction. Clin Appl Thromb Hemost 2003; 9: 333–6
- Bechtel M. J., Schaefer B. M., Kramer M. D. Plasminogen activator inhibitor type‐2 in the lesional epidermis of lupus erythematosus. Br J Dermatol 1996; 134: 411–19
- Patrassi G. M., Sartori M. T., Viero M. L., Scarano L., Boscaro M., Girolami A. The fibrinolytic potential in patients with Cushing's disease: a clue to their hypercoagulable state. Blood Coagul Fibrinolysis 1992; 3: 789–93
- Tassies D., Espinosa G., Munoz‐Rodriguez F. J., Freire C., Cervera R., Monteagudo J., et al. The 4G/5G polymorphism of the type 1 plasminogen activator inhibitor gene and thrombosis in patients with antiphospholipid syndrome. Arthritis Rheum 2000; 43: 2349–58
- Eroglu G. E., Kohler P. F. Familial systemic lupus erythematosus: the role of genetic and environmental factors. Ann Rheum Dis 2002; 61: 29–31
- Miller S. A., Dykes D. D., Polesky H. F. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988; 11;16: 1215
- Margaglione M., Grandone E., Di Minno G. Plasma predictors of ischemic complications of atherosclerosis: open issues. Biomed Pharmacother 1993; 47: 445–9
- Ruiz‐Quezada S., Vazquez‐Del Mercado M., Parra‐Rojas I., Rangel‐Villalobos H., Best‐Aguilera C., Sanchez‐Orozco L. V., et al. Genotype and allele frequency of PAI‐1 promoter polymorphism in healthy subjects from the west of Mexico. Association with biochemical and hematological parameters. Ann Genet 2004; 47: 155–62
- Akar N Y. E., Akar E., Avcu F., Yalcin A., Cin S. Effect of plasminogen activator inhibitor‐1 4G/5G polymorphism in Turkish deep vein thrombotic patients with and without FV1691 G‐A. Thromb Res 2000; 97: 227–30